Medications
Drug-specific guides covering what each medication is, how its dosing is typically structured in clinical trials, and what the latest outcomes data says — without crossing into prescribing advice.
18 articles
Medications
Survodutide Phase 3 data explained: what the SYNCHRONIZE trials found
Survodutide's Phase 3 trials showed 16.6% weight loss and 63% liver fat reduction at 76 weeks. Here's what the data means for patients — and what remains unknown.
5 min · Updated 2026-07-06
Medications
CagriSema: what it is, where it stands, and what the trial data actually show
Novo Nordisk's CagriSema achieved ~23% weight loss in Phase 3 trials but failed to demonstrate non-inferiority to tirzepatide in a head-to-head test. An NDA is under FDA review. Here's what patients following the pipeline need to know.
3 min · Updated 2026-06-17
Medications
CagriSema and REIMAGINE 2: what Phase 3 results mean for people with type 2 diabetes
Phase 3 REIMAGINE 2 data show CagriSema reduced HbA1c and weight significantly more than semaglutide alone in adults with type 2 diabetes — here's what patients need to understand.
5 min · Updated 2026-06-17
Medications
A third oral GLP-1 is in the pipeline. Here's what the Phase 2b data shows.
Phase 2b data shows aleniglipron achieved up to 11.3% placebo-adjusted weight loss at 36 weeks. Here's what that means for the oral GLP-1 pipeline.
4 min · Updated 2026-06-13
Medications
TRIUMPH-1 decoded: what retatrutide's Phase 3 results actually mean
TRIUMPH-1 found 28.3% mean weight loss at 80 weeks on 12mg retatrutide. Here's what that means — and what it doesn't yet.
4 min · Updated 2026-06-13
Medications
Why the oral Wegovy pill is 25mg, not 50mg: what OASIS 4 shows
The OASIS 4 trial found oral semaglutide 25mg led to 13.6% average weight loss in adults with obesity. Here's what the data shows and why the dose choice matters.
4 min · Updated 2026-06-10
Medications
Oral GLP-1 is here. Here's what early data show about who…
Two oral GLP-1 medications are now FDA-approved for weight management. Early real-world data show that most early adopters of the Wegovy pill are patients new…
5 min · Updated 2026-06-08
Medications
What's next in GLP-1 obesity treatment: the 2026 pipeline explained
A 2026 JAMA Medical News article examines three next-generation GLP-1 drugs with Phase 3 data. Here's what the evidence shows — and what it doesn't — for each.
7 min · Updated 2026-06-01
Medications
GLP-1 medications and the gut microbiome: what a 2026 review found
A 2026 review in the British Journal of Clinical Pharmacology found that GLP-1 drugs and gut bacteria influence each other in two directions. Here's what that means — and what it doesn't — for your treatment.
7 min · Updated 2026-06-01
Medications
GLP-1 medications and weight loss: what the sex differences data actually shows
A 2025 systematic review found women tend to lose more weight on GLP-1 medications than men. Here's what that means — and what it doesn't — for your treatment.
6 min · Updated 2026-06-01
Medications
Foundayo (orforglipron) is approved: what patients should know about the newest GLP-1 pill
FDA approved Foundayo (orforglipron) on April 1, 2026 — the first non-peptide oral GLP-1 with no food or water restrictions. Here's what to know before your next appointment.
5 min · Updated 2026-05-27
Medications
How retatrutide dosing appears in clinical trials
A research-framed summary of how retatrutide has been dosed in published trials. Retatrutide is investigational and not available by prescription.
6 min · Updated 2026-05-27
Medications
Tirzepatide explained (Mounjaro and Zepbound)
What tirzepatide is, how it differs from semaglutide, and the brand names it is sold under.
5 min · Updated 2026-05-27
Medications
How semaglutide dosing is typically structured
How clinicians generally think about semaglutide titration — starting low, escalating slowly, and what to discuss with your prescriber. Not a dosing instruction.
6 min · Updated 2026-05-27
Medications
What is retatrutide?
An overview of retatrutide — an investigational triple-hormone agonist being studied for obesity and metabolic disease, and why it is not yet available by prescription.
6 min · Updated 2026-05-27
Medications
What is semaglutide?
A plain-English explainer of semaglutide — what it is, how it works, the brand names it appears under, and what it is approved to treat.
6 min · Updated 2026-05-27
Medications
GLP-1 drugs and type 1 diabetes: what a 174,000-patient study found
A JHU study of 174,678 T1D patients found GLP-1 drugs linked to 15% lower cardiovascular risk and 19% lower kidney disease risk. Here's what that means — and what it doesn't.
5 min · Updated 2026-05-27
Medications
What the SURPASS-CVOT post-hoc analysis tells us about tirzepatide and cardiorenal outcomes
A JAMA Cardiology post-hoc analysis found tirzepatide reduced a 6-component cardiorenal endpoint by 16% vs dulaglutide over nearly 4 years. Here's what the primary vs post-hoc distinction means.
4 min · Updated 2026-05-27